Glioma Clinical Trial - MRI Contrast Clearance Analysis for Glioma Grading

Status Recruiting

Clinical Trial Summary

Gliomas are the most common primary brain tumor. Gliomas with different grades have different clinical behaviors that determine treatment planning and patient prognosis in clinical practice. In the 2021 World Health Organization (WHO) classification of tumors for the central nervous system, glioma genotyping was considered the most relevant information for neuroradiologists. The isocitrate dehydrogenase (IDH) genotype and 1p/19q codeletion status are two essential molecular markers that divide glioma into three groups: IDH wild-type, IDH mutant with 1p/19q non-codeletion, and IDH mutant with 1p/19q codeletion. MRI contrast clearance analysis (CCA) is based on T1 delayed-contrast subtraction map, Blue/tumor regions in CCA represent efficient clearance of contrast from the tissue (delayed signal<early signal), while red/nontumor regions in CCA represent contrast accumulation (delayed signal>early signal). However, there are not any reports on the role of MRI CCA in glioma grading and genotyping, Thus, We hypothesized that the proportion of blue/red region and their histogram analyses, which could be acquired for predicting IDH genotypes and 1p/19q codeletion in gliomas, and to assess the application of CCA in glioma grading.

Clinical Trial Description

This is a single-center bidirectional cohort study. The subjects of this study were patients diagnosed as glioma by pathological biopsy. Patients with suspicious mass will be performed extra 30 and 60 min after contrast agent application delayed T1-weighted sequences as same as before. Then enter the next experimental stage. (1) Image format conversion; (2) Registration;(3) Subtraction;(4) ROI segmentation;(5) ROI histogram analyses. Histogram parameters of blue and red ROI includes 1st、10th 、90th and 99th percentiles, mean, median, variance, skewness, and kurtosis. Finally, statistical methods were used to determine whether those parameters was statistically significant for IDH mutation status、1p/19q codeletion status and tumor grading. ;

Study Design

Related Conditions & MeSH terms

Glioma

Clinical Trial Details

NCT number	NCT06018870
Study type	Observational
Source	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Contact	Zifan Sang, M.M
Phone	+8618379873389
Email	952034224@qq.com
Status	Recruiting
Phase
Start date	June 1, 2023
Completion date	June 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04539574` - An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors	N/A
Enrolling by invitation	`NCT04461002` - Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
Terminated	`NCT01902771` - Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors	Phase 1
Completed	`NCT03242824` - The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma	Phase 2
Recruiting	`NCT04186832` - Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy	N/A
Completed	`NCT00424554` - Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)	Phase 2
Recruiting	`NCT05968053` - Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
Not yet recruiting	`NCT04550663` - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors	Phase 1
Completed	`NCT02805179` - A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma	Phase 2
Terminated	`NCT04556929` - Enhanced Detection in Glioma Excision	N/A
Not yet recruiting	`NCT06408428` - Glioma Intraoperative MicroElectroCorticoGraphy	N/A
Recruiting	`NCT06043232` - MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
Not yet recruiting	`NCT06043765` - Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training	N/A
Not yet recruiting	`NCT05025969` - Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
Completed	`NCT02978261` - Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	Phase 1
Terminated	`NCT01502605` - Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas	Phase 1
Completed	`NCT01836536` - Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients	N/A
Completed	`NCT01479686` - iMRI Guided Resection in Cerebral Glioma Surgery	Phase 3
Completed	`NCT01212731` - Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
Withdrawn	`NCT00985036` - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

MRI Contrast Clearance Analysis for Glioma Grading and Genotyping

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms